Perrigo Company (PRGO): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Perrigo Company ( PRGO) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.7%. By the end of trading, Perrigo Company fell $1.53 (-1.5%) to $102.67 on average volume. Throughout the day, 822,861 shares of Perrigo Company exchanged hands as compared to its average daily volume of 647,800 shares. The stock ranged in price between $102.56-$104.49 after having opened the day at $104.07 as compared to the previous trading day's close of $104.20. Other companies within the Health Care sector that declined today were: Neptune Technologies & Bioressources ( NEPT), down 22.8%, Tranzyme ( TZYM), down 19.1%, Opexa Therapeutics ( OPXA), down 18.6%, and Alimera ( ALIM), down 12.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. Perrigo Company has a market cap of $9.78 billion and is part of the drugs industry. The company has a P/E ratio of 22.9, above the S&P 500 P/E ratio of 17.7. Shares are up 7.1% year to date as of the close of trading on Friday. Currently there are six analysts that rate Perrigo Company a buy, one analyst rates it a sell, and seven rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Genvec ( GNVC), up 29.8%, Cormedix ( CRMD), up 23.5%, Arrhythmia Research Technology ( HRT), up 15.7%, and Vivus ( VVUS), up 13.9%, were all gainers within the health care sector with Intuitive Surgical ( ISRG) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

These Stocks Have Changed Direction

Stocks Tank as Trump, North Korea Exchange Barbs